Adding Everolimus Doubles PFS in AI-Resistant Metastatic Breast Cancer

The addition of everolimus to fulvestrant was associated with more than a doubling of progression-free survival in women with metastatic hormone receptor –positive, HER2-negative breast cancer who were resistant to aromatase inhibitor therapy.

Source: CancerNetwork - December 7, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Conferences/SABCS 2016 Source Type: news